These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2765375)

  • 1. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer.
    McKnight A; Mannell A; Shperling I
    Br J Cancer; 1989 Aug; 60(2):249-51. PubMed ID: 2765375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of tumour markers in the diagnosis of squamous-cell carcinoma of the esophagus.
    Dei Poli M; Albertino B; Gasparri G; Casalegno PA; Oliaro A; Rapellino M; Pecchio F
    Panminerva Med; 1990; 32(3):105-7. PubMed ID: 2077475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.
    Ching CK; Rhodes JM
    Br J Cancer; 1989 Jun; 59(6):949-53. PubMed ID: 2736232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
    Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
    Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of CA19-9 to detect asymptomatic colorectal carcinoma.
    Thomas WM; Robertson JF; Price MR; Hardcastle JD
    Br J Cancer; 1991 Jun; 63(6):975-6. PubMed ID: 2069854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19-9 in cases of esophageal cancer.
    Yilmaz O; Eroglu A; Dag E; Karaoglanoglu N; Yilmaz A
    Int J Clin Pract; 2006 Dec; 60(12):1604-8. PubMed ID: 16704680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor markers in squamous cell carcinoma of esophagus: immunometric assay in cytosol and membrane fraction.
    Gion M; Tremolada C; Mione R; Dittadi R; Della Palma P; Castoro C; Ruol A; Nosadini A; Peracchia A; Bruscagnin G
    Int J Biol Markers; 1990; 5(1):7-13. PubMed ID: 2230354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of tumor markers in the diagnosis of squamous carcinoma of the esophagus].
    Pecchio F; Albertino B; Ferrarotti G; Baldi S; Adamo R; Lo Faso C; Oliaro A; Dei Poli M; Rapellino M
    Minerva Chir; 1988 Sep; 43(18):1469-71. PubMed ID: 3226583
    [No Abstract]   [Full Text] [Related]  

  • 9. [Carbohydrate antigens in pleural effusion from patients with lung cancer].
    Hiratani K; Sakito O; Mukae H; Morikawa N; Kadota J; Fukushima K; Komori K; Hirota M; Hara K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jun; 27(6):673-8. PubMed ID: 2552211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients.
    Łukaszewicz-Zając M; Pączek S; Muszyński P; Kozłowski M; Mroczko B
    Clin Exp Med; 2019 May; 19(2):191-199. PubMed ID: 30820705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and tumour characteristics as prognostic markers for oesophageal cancer: a retrospective analysis of a cohort of patients at Groote Schuur Hospital.
    Dandara C; Robertson B; Dzobo K; Moodley L; Parker MI
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):629-34. PubMed ID: 25870217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
    Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
    Dis Esophagus; 1998 Jan; 11(1):35-9. PubMed ID: 9595230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of CA19-9 tumor antigen in the serum of patients with carcinomas.
    Wang FM; Tsai LC; Chang ZN; Han SH; Tsao D
    Proc Natl Sci Counc Repub China B; 1985 Apr; 9(2):119-25. PubMed ID: 3863154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
    Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
    Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
    J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical usefulness of tumor markers associated with pancreatic cancer].
    Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
    Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
    Haglund C
    Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F; Roscher R; Beger HG
    Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.